10.06.25 -- Can CHO Bioreactors Be Used For Plant-Based Protein Production?

Gene therapies are revolutionizing medicine, with AAV vectors leading the way. As production evolves, stable cell lines may replace transient transfection and unlock scalable solutions.

Mesenchymal Stem Cells (MSCs) hold immense therapeutic promise. Can we harness their potential by making them more like consistent cell lines, without losing their unique advantages? Let's explore.

Glycoprotein therapies face variable glycan profiles. An alternative approach, IVGE, moves modification outside the cell for true molecular control, ensuring consistency and speed.

In AAV manufacturing, long-term success depends not just on titers, but on maximizing the percentage of full capsids to ensure efficacy, safety, and scalability.

See how the recently described cell line development paradigm shift, enabled by the Leap-In transposon platform, can extend to the development of bispecific monoclonal antibody-producing cell substrates.

Master orbital throw by understanding its impact on aeration, mixing, and growth. Explore recommendations for various applications and the benefits of adjustable throw incubator shakers.

In cell culture, the leakage of toxic or inhibitory chemicals from single-use bioreactors has become a growing concern. Explore recommendations for leachable studies.